Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of...

Full description

Bibliographic Details
Main Authors: Sonam Puri, Michael Shafique
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-01-01
Series:Drugs in Context
Subjects:
anti-ctla-4
anti-pd-1/pdl-1
lung cancer
Online Access:https://www.drugsincontext.com/combination-checkpoint-inhibitors-for-treatment-of-non-small-cell-lung-cancer:-an-update-on-dual-anti-ctla-4-and-anti-pd-1-pd-l1-therapies/
id doaj-2977623cf8db4d6d9db7781188795744
record_format Article
spelling doaj-2977623cf8db4d6d9db77811887957442020-11-25T00:13:13ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-01-01911110.7573/dic.2019-9-2Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapiesSonam PuriMichael ShafiqueImmunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of the treatment armamentarium in NSCLC. This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade. Despite the challenges, this paper also presents some solutions and ways to improve our understanding and implementation of such combinations in the future.https://www.drugsincontext.com/combination-checkpoint-inhibitors-for-treatment-of-non-small-cell-lung-cancer:-an-update-on-dual-anti-ctla-4-and-anti-pd-1-pd-l1-therapies/anti-ctla-4anti-pd-1/pdl-1lung cancer
collection DOAJ
language English
format Article
sources DOAJ
author Sonam Puri
Michael Shafique
spellingShingle Sonam Puri
Michael Shafique
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
Drugs in Context
anti-ctla-4
anti-pd-1/pdl-1
lung cancer
author_facet Sonam Puri
Michael Shafique
author_sort Sonam Puri
title Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
title_short Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
title_full Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
title_fullStr Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
title_full_unstemmed Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
title_sort combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-ctla-4 and anti-pd-1/pd-l1 therapies
publisher BioExcel Publishing Ltd
series Drugs in Context
issn 1740-4398
1740-4398
publishDate 2020-01-01
description Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of the treatment armamentarium in NSCLC. This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade. Despite the challenges, this paper also presents some solutions and ways to improve our understanding and implementation of such combinations in the future.
topic anti-ctla-4
anti-pd-1/pdl-1
lung cancer
url https://www.drugsincontext.com/combination-checkpoint-inhibitors-for-treatment-of-non-small-cell-lung-cancer:-an-update-on-dual-anti-ctla-4-and-anti-pd-1-pd-l1-therapies/
work_keys_str_mv AT sonampuri combinationcheckpointinhibitorsfortreatmentofnonsmallcelllungcanceranupdateondualantictla4andantipd1pdl1therapies
AT michaelshafique combinationcheckpointinhibitorsfortreatmentofnonsmallcelllungcanceranupdateondualantictla4andantipd1pdl1therapies
_version_ 1725395635995148288

Similar Items